CDK4/6 as a therapeutic target in malignant melanoma

被引：0
|
作者：
Teh, Jessica L. [1 ]
Aplin, Andrew [1 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-3096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3096
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
    Asciolla, James J.
    Wu, Xuewei
    Adamopoulos, Christos
    Gavathiotis, Evripidis
    Poulikakos, Poulikos I.
    NATURE CANCER, 2025, 6 (01) : 24 - 40
  • [42] Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
    O'Brien, Neil A.
    McDermott, Martina S.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Loson, Oliver
    Chau, Kevin
    Jia, Weiping
    Kamranpour, Naeimeh
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Glaspy, John A.
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
    Emily J. Lelliott
    Karen E. Sheppard
    Grant A. McArthur
    npj Precision Oncology, 6
  • [44] Investigating the effect of CDK4/6 and MDM2 inhibition on melanoma
    Slesur, Lauren
    Vilgelm, Anna
    Al-Rohil, Rami
    Richmond, Ann
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [45] CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
    Sun, Ran
    Wang, Xuemei
    Zhang, Leichao
    Gu, Yu
    Yang, Shaojuan
    Wang, Liping
    Wang, Xueju
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
    Lelliott, Emily J.
    Sheppard, Karen E.
    McArthur, Grant A.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [47] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [48] Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
    Elisabet Aliagas
    Ania Alay
    Maria Martínez-Iniesta
    Miguel Hernández-Madrigal
    David Cordero
    Mireia Gausachs
    Eva Pros
    Maria Saigí
    Sara Busacca
    Annabel J. Sharkley
    Alan Dawson
    Ramón Palmero
    José C. Ruffinelli
    Susana Padrones
    Samantha Aso
    Ignacio Escobar
    Ricard Ramos
    Roger Llatjós
    August Vidal
    Eduard Dorca
    Mar Varela
    Montse Sánchez-Céspedes
    Dean Fennell
    Cristina Muñoz-Pinedo
    Alberto Villanueva
    Xavi Solé
    Ernest Nadal
    British Journal of Cancer, 2021, 125 : 1365 - 1376
  • [49] CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma.
    Matsumoto, Seiji
    Fukuda, Akihiro
    Nakamichi, Toru
    Nakamura, Akifumi
    Kuroda, Ayumi
    Hashimoto, Masaki
    Takuwa, Teruhisa
    Kondo, Nobuyuki
    Hasegawa, Seiki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
    Aliagas, Elisabet
    Alay, Ania
    Martinez-Iniesta, Maria
    Hernandez-Madrigal, Miguel
    Cordero, David
    Gausachs, Mireia
    Pros, Eva
    Saigi, Maria
    Busacca, Sara
    Sharkley, Annabel J.
    Dawson, Alan
    Palmero, Ramon
    Ruffinelli, Jose C.
    Padrones, Susana
    Aso, Samantha
    Escobar, Ignacio
    Ramos, Ricard
    Llatjos, Roger
    Vidal, August
    Dorca, Eduard
    Varela, Mar
    Sanchez-Cespedes, Montse
    Fennell, Dean
    Munoz-Pinedo, Cristina
    Villanueva, Alberto
    Sole, Xavi
    Nadal, Ernest
    BRITISH JOURNAL OF CANCER, 2021, 125 (10) : 1365 - 1376
12345